BRD-6929

Mechanism of Action: This benzamide scaffold is suitable for customers studying acetylation-linked regulation of protein stability. Through HDAC-associated chemical space, it may help evaluate how chromatin state, acetylation balance, and transcriptional remodeling influence expression or degradation sensitivity of proteins involved in proteostasis pathways.

• PROTAC Ligand for E3 Recruitment: Use 4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide as a targeting moiety within PROTAC constructs to engage a specific protein of interest. By coupling it to an E3 ligase-recruiting ligand, researchers can test whether ternary complex formation drives ubiquitination and subsequent proteasome-dependent degradation.

• Ternary Complex Optimization Studies: Incorporate this ligand into PROTAC linkers of varying length and composition to tune spatial orientation toward the target protein and the E3 ligase. Systematic optimization can assess degradation potency versus binding affinity, using biochemical and cell-based assays to quantify ternary complex stability and degradation kinetics.

• Structure-Guided Degrader Design: Apply medicinal chemistry and structure-guided modeling to refine substituents and linker attachment points on this benzamide scaffold. The goal is to improve target engagement while maintaining productive E3 ligase proximity, enabling more efficient ubiquitin recruitment and enhanced selective degradation across relevant cellular contexts.

• Targeted Degradation Mechanism Probing: Employ PROTACs built with this ligand to interrogate degradation mechanisms, including dependence on ubiquitination, proteasome activity, and E3 ligase engagement. Mechanistic validation using pathway inhibitors and competition experiments helps confirm that observed loss of target protein arises from targeted proteolysis rather than transcriptional or translational effects.

4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide is a HDAC target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of 4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.